The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The plant is expected to enhance regional supply capabilities
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
